Patient Phenotype Advisory Board
Patient Phenotype Advisory Board
The Client
One of the world’s largest pharma companies
The Need
To gain feedback from mental health experts on potential patient phenotypes for a new drug entering Phase 2 trials.
The Action
During a 4-hour virtual advisory board, external advisors were asked to review and discuss three different potential phenotypes for major depressive disorders, borderline personality disorder, and post-traumatic stress disorder. In particular, feedback was sought on how well these phenotypes align with the mechanism of action of a new drug. My role was to document the discussion of approximately 18 participants.
The Outcome
A 9,000 word meeting report to inform Phase 2 and Phase 3 product development.
Senior Account Director
Â
“The advisory board and final report had a significant impact on strategic decisions for Phase 2 and 3, particularly around the most compelling evidence to collect for specific patient phenotypes.”
The advisory board and final report had a significant impact on strategic decisions for Phase 2 and 3, particularly around the most compelling evidence to collect for specific patient phenotypes.
The client
One of the world’s largest pharma companies
Senior Account Director
The need
To gain feedback from mental health experts on potential patient phenotypes for a new drug entering Phase 2 trials.
The action
During a 4-hour virtual advisory board, external advisors were asked to review and discuss three different potential phenotypes for major depressive disorders, borderline personality disorder, and post-traumatic stress disorder. In particular, feedback was sought on how well these phenotypes align with the mechanism of action of a new drug. My role was to document the discussion of approximately 18 participants.
A 9,000 word meeting report to inform Phase 2 and Phase 3 product development.